



#### Contents +

| nvitation   | 3  |
|---|----|
| Program at a Glance                                 | 4  |
| xhibition Center I - Venue Information              | 5  |
| GOG Semi-Annual Meeting Agenda                      |    |
| Cancer Prevention & Control Committee               | 7  |
| Cervix, Vulva, Vagina Committee                     | 8  |
| Data Safety Monitoring Board Committeee             | 9  |
| Developmental Diagnostic and Therapeutics Committee | 10 |
| Industrial Session – Introduction of Pipelines      | 11 |
| International Session                               | 12 |
| KGOG Report   | 13 |
| Ovary-Fallopian tube Committee                      | 14 |
| Publication Committee                               | 15 |
| Rare Tumor Committee                                | 16 |
| Scientific Review Board Committee                   | 17 |
| Special Session I (KGOG 2029/SELYE)                 | 18 |
| Special Session II (KGOG 1047/DEBULK)               | 19 |
| Special Session III (KGOG 4002/GYANT)               | 20 |
| Statistics and Data Committee                       | 21 |
| Surgery Committee                                   | 22 |
| Translational Research Committee                    | 23 |
| Uterine Corpus-GTT Committee                        | 24 |
| Satellite Symposium I                               | 26 |
| Satellite Symposium II                              | 27 |
| Satellite Symposium III                             | 28 |
| nformation  | 29 |
| Ву КТХ & Мар  | 30 |







#### **Invitation +**

I am truly grateful to introduce the KGOG 2022 Spring Semi-Annual Meeting at BEXCO, Busan.

KGOG has held small committee-centered academic meetings once or twice a month, examining the clinical trials conducted in South Korea and striving to develop new research protocols. Thanks to our enthusiastic members, clinical outcomes are being accumulated even amidst the poor environment of the COVID-19 era. I take great pride in this both as the president and a member

For this Semi-Annual Meeting, one of the collective meetings for KGOG members that are hosted four times a year, we have again organized the program with content focused on clinical trials from start to the end under active participation from our members. For this meeting, we considered how we always ran out of meeting time and thus included a day and a half more in the program. The event will be conducted in the structure of an Academic Business format that is different from general conferences, and attending members consist of professors in gynecology (majoring in gynecology), radiology, and medical oncology and CRAs (Clinical Research Associates), as well as members related to clinical trials of multinational pharmaceutical companies.

Currently, South Korea accounts for a significant portion of worldwide clinical-trial competencies. Of course, it is a fact that most are constituted by clinical trials supported by multinational pharmaceutical companies, and our KGOG's product, KGOG-led IIT research, still has parts that need to be cultivated in the quantitative and qualitative aspects.

To achieve meaningful research results, you need ideas, skilled personnel, and adequate research funding. KGOG executives, members, and CRAs are working today to secure research funds and create ideas under the name of KGOG.

Lastly, if motivated researchers approach KGOG at any time, we have low barriers to help you and your leaders conduct clinical trials.

Thank You.

#### Hello?

We thank and welcome the members who attended this Semi-Annual Meeting of KGOG despite the tough era of COVID19 pandemic.

This SAM was prepared to the extension of the changed format and content at the last SAM. We have prepared a workshop for each committee, focusing on the approved studies in development and the progress of proposed studies. We also have prepared Special Sessions for promising new studies, and Industrial Session. Thank you to committee the chairs, co-chairs, secretaries, and members of each committee for preparing and presenting this workshop held simultaneously in a total of 3 rooms.

Although some committees cannot participate in this SAM, we hope that this SAM will serve as an opportunity for the studies of KGOG to advance one step further.

Thank you.



Kim, Jae-Hoon President of KGOG



Choi, Min Chul Program Director of KGOG



## Program at a Glance +


|             | Room D   |
|-------------|--|
| 15:00-16:00 | Developmental Diagnostic and<br>Therapeutics Committee |
| 16:10-16:55 | Special Session I<br>(KGOG 2029/SELYE)                 |
| 17:05-17:50 | Special Session II<br>(KGOG 1047/DEBULK)               |

|             | Room E   |
|-------------|--|
| 14:30-15:00 | Scientific Review Board<br>Committee (closed)      |
| 15:00-15:50 | Statistics and Data Committee                      |
| 16:00-16:30 | Publication Committee (closed)                     |
| 16:30-17:00 | Data Safety Monitoring Board<br>Committee (closed) |
| 17:00-17:50 | Translational Research<br>Committee                |

Date: May 14 (Sat.), 2022 Venue: BEXCO, Busan Exhibition Center I

|             | Room A<br>Main Hall 3F (314-317)   | Room B<br>3F (312-313)                   | Room C<br>2F (212-213)                   |
|-------------|--|--|--|
| 08:00-08:30 |  | Operation Committee (closed)             |  |
| 08:30-10:10 | Ovary-Fallopian tube Committee<br>-Special Session IV :<br>SBRTx in recurrent OV cancer- |  |  |
| 10:20-12:00 | Cervix, Vulva, Vagina Committee<br>-Special Lecture (Pathology)-                         |  |  |
| 12:10-12:30 | KGOG Report  |  |  |
| 12:30-13:20 | Satellite Symposium I  | Satellite Symposium II                   | Satellite Symposium III                  |
| 13:30-14:20 | Surgery Committee  | International Session                    | Special Session III<br>(KGOG 4002 GYANT) |
| 14:30-15:30 | Rare Tumor Committee   | Cancer Prevention & Control<br>Committee | Industrial Session                       |
| 15:40-17:00 | Uterine Corpus-GTT Committee   |  |  |

## **Exhibition Center I - Venue Information**



200-inch Electric Screen

200-inch Electric Screen

300-inch Electric Screen




## **Exhibition Center I - Venue Information**

# **2F** Exhibition Center 211–218

# Artisential Lounge 212-213 Booth Exhibition

# **3F** Exhibition Center 311–317



# KGOG Semi-Annual Meeting Agenda +

## **Cancer Prevention & Control Committee**

| Date  | 2022. 5. 14.                   |
|-------|--------------------------------|
| Time  | 14:30-15:30                    |
| Place | Room B                         |
| Chair | Kim, Ki Hyung/Lim, Myong Cheol |

## **Workshop Agenda**

| 1. | Physical activity & Diet for prevention of endometrial cancers: What needs to be done in the cohort-based trial setting? | Kim, Jeong Seon (8 min) |
|----|--|-------------------------|
| 2. | Protocol on oral contraceptives & Breastfeeding for prevention of gynecologic cancers.                                   | Eoh, Kyung Jin (8 min)  |
| 3. | Can we establish the protocol for OCCR/BCCR-based genetic counseling?  | Ha, Hyeong In (8 min)   |
| 4. | Ovarian cancer risk factors beyond HR PV/LPV: Can we estimate them objectively?  | Choi, Youn Jin (8 min)  |

5. Panel discussion

Chung, Dae Hoon/Shin, So Jin/Lee, San Hui/Kim, Hee Seung/Park, Eun Young/Chang, Yoon Jung (22 min)

6. Distillation Nam, Eun Ji (5 min)

## Cervix, Vulva, Vagina Committee

| Date  | 2022. 5. 14.               |
|-------|----------------------------|
| Time  | 10:20-12:00                |
| Place | Room A                     |
| Chair | Lee, Keun Ho/Kim, Sang Wun |

## **Workshop Agenda**

1. Introduction Lee, Keun Ho (1 min)

2. Review of ongoing study (25 min)

A. Overview of ongoing study

Jung, Yong Wook (5 min)

B. KGOG1043/A randomized, open-label phase 3 trial of Tisotumab vedotin Vs. investigator's choice chemotherapy in second or third line recurrent or metastatic cervical cancer

C. KGOG1044/Feasibility of HPV DNA and vaginal infectious disease detection in mail-delivered self obtained vaginal sample obtained by G+kit (SELPAX-I)

D. KGOG1046/Adjuvant chemotherapy versus radiotherapy for postoperative cervical cancer: A phase III trial (AFTER)

Shim, Seung-Hyuk (4 min)

E. KGOG1047/Therapeutic effect of surgical debulking of metastatic lymph nodes in cervical cancer stage III Cr. A phase III, randomized controlledclinical trial (DEBLILK trial)

Roh, Ju Won (4 min)

Lee, Sung Jong (4 min)

→ Special Session II (KGOG 1047/DEBULK)

3. Special Lecture I: Consideration when conduct clinical trials of gynecologic cancer as radiation oncologist (17 min)

Eom, Keun-Yong (15 min)
- Discussion Yoon, Bo Seong (2 min)

4. Proposal of new concepts (30min)

A. COnization Before minimally invasive RAdical hysterectomy in 2018 FIGO stage

Lee, Maria (10 min)

IB1 cervical cancer (COBRA-1)

- Discussion Paek, Jiheum (5 min)

B. The comparison of proportion of positive resection margin by use of Lugol's solution during LEEP and the identifications of predictors for residual tumor: A phase III, randomized controlled trial (Lugol trial)

Roh, Ju Won (10 min)

- Discussion

Cho, Sang Hyun (5 min)

 Special Lecture II: Introduction of Silva Pattern in Endocervical Adenocarcinoma as an Important Determinant for Pelvic Lymph Node Dissection Kim, Kyu Rae (Asan Medical Center) (30 min)

i. Closing Kim, Sang Wun (1 min)

## **Data Safety Monitoring Board Committee (Closed)**

| Date          | 2022. 5. 13.  |
|---------------|---|
| Time          | 16:30~17:00   |
| Venue On Site | Room E, (COSMOS), 2 <sup>nd</sup> Fl., The Westin Josun Busan |
| Chair         | Lee, Sun Joo  |

### **Workshop Agenda**

1. Report of KGOG DSMB meetings in 2021 Lee, Sun Joo (5 min)

2. Key considerations for successful operation of DSMB in KGOG Nam, Byung Ho (20 min)

3. Questions/Discussion (5 min)

## **Developmental Diagnostic and Therapeutics Committee**

| Date            | 2022. 5. 13.   |
|-----------------|--|
| Time            | 15:00-16:00  |
| Venue On Site   | Room D, (TULIP) 2 <sup>nd</sup> FI., The Westin Josun Busan                |
| Zoom<br>Address | https://us02web.zoom.us/j/3523850131<br>ID: 352 385 0131<br>Password: 2022 |
| Chair           | Kim, Kidong  |

## **Workshop Agenda**

1. Introduction Kim, Kidong (1 min)

2. Review of ongoing/approved/proposed studies Kim, Kidong (6 min)

- A. Association of cul-de-sac seeding with intraperitoneal tumor burden in advanced ovarian cancer (CIEL)
- B. Characteristics of GYnecological surgery using Articulated laparoscopic iNsTruments (GYANT)
- → Special Session III (KGOG 4002/GYANT): Room C/13:30
- C. Study on the clinical utility of CIRCUlating tumor DNA methylation in the Screening of cervical and ovarian cancers (CIRCUS)
- D. Chemotherapy after (CC)RT in Locally advanced cErvical cAncer with high Risk factors (CLEAR)
- 3. Other DDT activities

DDT seminar Park, Hyun (3 min)

4. New study

Vi-sealer (KHIDI grant proposed) Park, Hyun (10 min)

5. Invited lecture

Adhesive Protein as an Innovative Functional Biomaterial for Localized Cancer Therapies

Cha, Hyung Joon (POSTECH)
(30 min)

6. Closing

## **Industrial Session – Introduction of Pipelines**

| Date  | 2022. 5. 14.                   |
|-------|--------------------------------|
| Time  | 14:30-15:30                    |
| Place | Room C                         |
| Chair | Ryu, Sang Young/Kim, Hee Seung |

## **Workshop Agenda**

1. Pipeline in oncology: Moving from research to patients

Bernhardt, Alf

(GMAO, Takeda Pharmaceuticals International AG)

(15 min)

2. From concept to practice: new era of precision medicine from GSK (Kyung Hee University Hospital at Gangdong)

(15 min)

3. Data-driven approaches to immunotherapy and beyond Kim, Yohan (MSD) (15 min)

4. AstraZeneca Early Oncology Portfolio

Kim, Rosa HeeJung
(Director of External R&D scientific and clinical alliances lead in Asia)

(15 min)

## **International Session**

|   | Date  | 2022. 5. 14.                |
|---|-------|-----------------------------|
| ĺ | Time  | 13:30-14:20                 |
|   | Place | Room B                      |
| ĺ | Chair | Lee, Chulmin/Lee, Sung Jong |

# **Workshop Agenda**

1. Report of Asia-Pacific Gynecologic Oncology Trials Group (APGOT) Kim, Byoung Gie (20 min)

2. Report of East Asian Gynecologic Oncology Trials Group (EAGOT) Kim, Young Man (20 min)

3. Discussion (10 min)

# **KGOG Report**

| Date  | 2022. 5. 14.  |
|-------|---------------|
| Time  | 12:10-12:30   |
| Place | Room A        |
| Chair | Kim, Jae Wook |

## **Workshop Agenda**

1. 20 years history of KGOG Min, Kyung Jin (5 min)

2. Renewal homepage of KGOG Song, Jae Yun (5 min)

3. Congratulatory message Kang, Soon-Beom (5 min)

## **Ovary-Fallopian tube Committee**

| Date  | 2022. 5. 14.                |
|-------|-----------------------------|
| Time  | 08:30-10:10                 |
| Place | Room A                      |
| Chair | Kang, Sokbom/Lee, Jeong-Won |

## **Workshop Agenda**

- 1. Introduction/Review of on-going studies (5 min)
- 2. Protocol Review (16 min)
  - A. i. Phase III randomized clinical trial for stage III epithelial ovarian cancer randomizing between primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (KGOG 3062/OV-HIPEC2)
  - A. ii. Niraparib with or without bevacizumab in maintenance after complete cytoreduction in patients with ovarian cancer (KGOG 3063/NIRVANA-1)
  - B. Phase II trial evaluation the Efficacy and safety of physician chosen Chemotherapy with hormonal therapy in patientS with heavily treated Advanced epithelial ovarian, fallopian, tube or primary peritoneal cancer: A multicenter piolt study(KGOG 3049/ELSA trial)
- 3. Special Session IV: SBRTx for recurrent ovarian cancer (40 min)

A Phase III multicenter study on the additional effect of stereotactic body radiation therapy to standard treatment for recurrent ovarian cancer

Kim, Yong Bae (30 min)

Lim, Myong Cheol (8 min)

Lee, Banghyun (8 min)

- Discussion

Kim, Mi Kyung (10 min)

4. Special Lecture (30 min)

Fatal toxicity of PARPi maintenance of ovarian cancer: How do we offer appropriate monitoring and investigat

Jung, Ki Sun (30 min)

## **Publication Committee (Closed)**

| Date          | 2022. 5. 13.  |
|---------------|---|
| Time          | 16:00~16:30   |
| Venue On Site | Room E, (COSMOS), 2 <sup>nd</sup> Fl., The Westin Josun Busan |
| Chair         | Jeon, Seob/Lee, Sung-Jong                                     |

| W  | Workshop Agenda   |                          |
|----|---|--------------------------|
| 1. | Introduction  | Jeon, Seob (2 min)       |
| 2. | Development of application form to Publication committee        | Chang, Ha Kyun (7 min)   |
| 3. | Review of published Article of KGOG in 2021                     | Lee, Young Jae (7 min)   |
| 4. | Review of published Abstract of KGOG in 2021                    | Kim, Ji Hye (7 min)      |
| 5. | Future Agenda & Brain storming of Publication committee in 2022 | Lim, Myong Cheol (7 min) |

#### **Rare Tumor Committee**

| Date  | 2022. 5. 14.                |
|-------|-----------------------------|
| Time  | 14:30-15:30                 |
| Place | Room A                      |
| Chair | Choi, Chel Hun/No, Jae Hong |

## **Workshop Agenda**

1. Introduction (3 min)

2. Review of topics

Stratified mucin-producing intraepithelial lesion (SMILE) and invasive stratified mucin producing carcinoma (ISMC) of the uterine cervix

Kim, Hyun-Soo (20 min)

3. Progress of Proposed Studies (21 min)

A. Optimized therapeutic strategy for recurrent ovarian clear cell carcinoma with ARID1A status (OTC)

Kim, Tae Eun (5 min)

B. Clinical characteristics and prognosis in HPV independent cervical adenocarcinoma

Chang, Ha Kyun (5 min)

C. Radical vs. fertility sparing surgery in intraepithelial mucinous carcinoma of ovary

Shim, Seung-Hyuk (5 min)

D. MIS vs. open surgery in rare histology cervical cancer

Kim, Se lk (2 min)

E. A MRI-based machine learning approach for distinguishing uterine sarcoma from leiomyomas

Kim, Tae Hun (2 min)

F. BRCA status in epithelial ovarian cancer with other than serous and endometrioid adenocarcinoma

Kim, Tae Hun (2 min)

4. Proposal of new concepts (10 min)

A. Accuracy of cytology (PAP) in HPV independent cervical cancer

Chang, Chi-Son/ Choi, Chel Hun (5 min)

B. Discussion (5 min)

5. Closing (2min)

## **Scientific Review Board Committee (Closed)**

| Date          | 2022. 5. 13.  |
|---------------|---|
| Time          | 14:30~15:00   |
| Venue On Site | Room E, (COSMOS), 2 <sup>nd</sup> Fl., The Westin Josun Busan |
| Chair         | Kim, Jae Hoon   |

## **Workshop Agenda**

1. How does SRB review means an intrestigator? Lee, Shin-Wha (15 min)

SRB SOP reviewLee, Shin-Wha (5 min)

3. SRB Report 2021/2022 Lee, Shin-Wha (5 min)

4. Discussion (5 min)

## Special Session I (KGOG 2029/SELYE)

| Date            | 2022. 5. 13.   |
|-----------------|--|
| Time            | 16:10-16:55  |
| Venue On Site   | Room D, (TULIP) 2nd Fl., The Westin Josun Busan                            |
| Zoom<br>Address | https://us02web.zoom.us/j/3523850131<br>ID: 352 385 0131<br>Password: 2022 |
| Chair           | Park, Jeong-Yeol   |

## **Workshop Agenda**

KGOG 2029/SELYE: Prospective randomized comparison of sentinel lymph node mapping using indocyanine green and conventional pelvic lymph node dissection in clinical stage I/II endometrial cancer

Pelvic and paraaortic sentinel lymph node mapping: standardization of surgical technique

Lee, Keun Ho (15 min)

 Retrospective study and survey study of sentinel lymph node mapping in endometrial cancer and cervical cancer: SELYE-R & SELYC-R Shim, Seung-Hyuk (15 min)

3. Progress of KGOG 2029/SELYE

Park, Jeong-Yeol (and all investigators) (15 min)

# **Special Session II (KGOG 1047/DEBULK)**

| Date            | 2022. 5. 13.   |
|-----------------|--|
| Time            | 17:05~17:50  |
| Venue On Site   | Room D, (TULIP) 2nd Fl., The Westin Josun Busan                            |
| Zoom<br>Address | https://us02web.zoom.us/j/3523850131<br>ID: 352 385 0131<br>Password: 2022 |
| Chair           | Roh, Ju Won  |

## **Workshop Agenda**

KGOG 1047/DEBULK: Therapeutic effect of surgical debulking of metastatic LNs in cervical cancer stage IIICr

1. Summary of study status

Roh, Ju-Won (10 min)

2. RT guide and QC plan

Kim, Yong Bae (10 min)

3. Future research time schedule and patient registration strategy

Yun, Bo Seong (and all investigators) (10 min)

## Special Session III (KGOG 4002/GYANT)

| Date  | 2022. 5. 14. |
|-------|--------------|
| Time  | 13:30-14:00  |
| Place | Room C       |
| Chair | Kim, Kidong  |

## **Workshop Agenda**

KGOG 4002/GYANT: Characteristics of Gynecological surgery using Articulated laparoscopic iNsTruments

1. Summary of study status Kim, Kidong (10 min)

2. Planned analysis and authorship discussion All investigators (10 min)

3. Idea for further studies (analysis, grants)

All investigators (10 min)

## **Statistics and Data Committee**

| Date            | 2022. 5. 13.   |
|-----------------|--|
| Time            | 15:00~15:50  |
| Venue On Site   | Room E, (COSMOS), 2 <sup>nd</sup> Fl., The Westin Josun Busan              |
| Zoom<br>Address | https://us02web.zoom.us/j/3480171532<br>ID: 348 017 1532<br>Password: 2022 |
| Chair           | Cho, Hanbyoul  |

# **Workshop Agenda**

| Workshop Agenda |   |                                   |
|-----------------|---|-----------------------------------|
| 1.              | Introduction  | Cho, Hanbyoul                     |
| 2.              | Review of new changes in data management of KGOG  | Han, Gwan Hee (3 min)             |
| 3.              | Review of ongoing study with new data management (12 min)   |                                   |
|                 | A. Characteristics of GYnecological surgery using Articulated laparoscopic iNsTruments (KGOG 4002/GYANT)  | Kim, Ki Dong (3 min)              |
|                 | B. Effectiveness and safety of PARP-inhibitor therapy in recurrent ovarian cancer patients in real world: Ambidirectional multicenter cohort study (KGOG 3058/ESPOIR)                                 | Choi, Hyun Jin (3 min)            |
|                 | C. A cohort study to assess the safety and efficacy of PARP inhibitor maintenance after first-line therapy of Korean women with advanced ovarian/fallopian/peritoneal cancer (KGOG 3059/PMFO)         | Lee, Eun Ju (3 min)               |
|                 | D. Prospective randomized comparison of Sentinel Lymph Node Mapping Using Indocyanine Green and conventional pelvic lymph node dissection in Clinical Stage I II Endometrial Cancer (KGOG 2029/SELYE) | Park, Jeong-Yeol (3 min)          |
| 4.              | Current data management in LSK SMO (10 min)   | Kim, Hyejin (10 min)              |
| 5.              | Digital healthcare innovation in Roche (25 min)   | Rhee, Woojin (20 min)             |
|                 | Discussion  | Choi, Youn Jin/Kim, Se lk (5 min) |
|                 |   |                                   |

Cho, Hanbyoul

20 Korean Gynecologic Oncology Group

KGOG 2022 Semi-Annual Meeting | May 14 [Sat.], 2022 21

6. Closing

## **Surgery Committee**

| Date  | 2022. 5. 14.             |
|-------|--------------------------|
| Time  | 13:30-14:20              |
| Place | Room A                   |
| Chair | Hong, Dae Gy/Lee, Eun Ju |

## **Workshop Agenda**

1. Introduction Lee, Eun Ju (1 min)

2. Review of ongoing study (20 min)

A. KGOG 4004 (OVsurg-2102-1): A survey on peritonectomy procedure in debulking Kim, Myeong Seon (5 min) operation of advanced ovarian, fallopian, peritoneal cancer

B. KGOG 4005 (OVsurg-2101): The analysis of the patients who have received reoperation whining 30 days after debulking operation for primary advanced epithelial ovarian, tubal, peritoneal cancer Lim, Myong Cheol (5 min)

C. OVsurg-2103: The analysis of 90-day postoperative mortality after debulking operation for primary advanced epithelial ovarian, tubal, peritoneal cancer Song, Yong Jung (5 min)

D. OVsurg-2108: Assessment of QoL after LAR or visceral peritoneal stripping during cytoreductive surgery for AEOC: prospective cohort study (LAPSODY) trial

Park, Soo Jin (5 min)

3. Progress of Proposed Studies (5 min)

 A. OVsurg-2106: Selection Criteria for Omitting Interval debulking surgery after neoadjuvant chemotherapy for high grade serous carcinoma of the ovary (SCORE study) Kim, Hee Seung (5 min)

4. Proposal of new concepts (20 min)

A. OVsurg-2102-2: Total versus selective peritonectomy during interval debulking operation: Prospective study

Lee, Yoo Young (5 min)

A. - Discussion (5 min)

B. - Discussion (5 min)

B. Surgical Treatment of lymphedema

Lee, Joon Seok (5 min)

5. Closina

Hong, Dae Gy (1 min)

#### **Translational Research Committee**

| Date            | 2022. 5. 13.   |
|-----------------|--|
| Time            | 17:00~17:50  |
| Venue On Site   | Room E, (COSMOS), 2 <sup>nd</sup> Fl., The Westin Josun Busan              |
| Zoom<br>Address | https://us02web.zoom.us/j/3480171532<br>ID: 348 017 1532<br>Password: 2022 |
| Chair           | Lee, Jeong-Won/Lee, Sung Jong  |

## **Workshop Agenda**

- 1. Introduction (3 min)
- 2. Review of topics (45 min)

A. Real world analysis of HRD testing in EOC patients

Paik, E Sun (15 min)

B. Process of Bench Research to Clinical Trials

Noh, Joseph (15 min)

C. Who will be the last survivor? Somatic BRCA Mutation-Based Drug Response and Survival Prediction Study in EOC patients

Kim, Ji Hye (15 min)

- 3. Discussion (5 min)
- 4. Closing (2 min)



| Date  | 2022. 5. 14.                  |
|-------|-------------------------------|
| Time  | 15:40-17:00                   |
| Place | Room A                        |
| Chair | Kim, Min Kyu/Park, Jeong-Yeol |

## **Workshop Agenda**

1. Introduction Kim, Min Kyu (1 min)

2. Review of ongoing study Lee, Maria/Kim, Min Kyu (2 min)

- Active: 2020, 2021 (TREE PRO), 2022 (NRG GY018), 2024, 2026 (RACHEL), 2029
- ✓ Not Enrolling: 2025 (AtTend), 2028, 2030, 2031 (JGOG 2051)
- 3. Review of Closed Study (1 min)
- 4. Progress of Proposed Studies (5 min)
  - 4-1. KGOG 2015 ancillary study
  - 4-2. COPIA
  - 4-3. Microbiome
  - 4-4. Precision Hysteroscopy
- 5. Proposal of new concepts (20 min)

| 5-1. Radical hysterectomy in Endometrial cancer with Cervical involvemENT (RECENT)  | Kim, Seong Min (3 min) |
|---|------------------------|
| Discussion (2 min)  | Son, Joo-Huk (2 min)   |
| 5-2. Characteristics, risk factors, and prognosis of incidentally diagnosed uterine neoplasms: a multi-institutional review study | Baek, Min-Hyun (3 min) |
| Discussion (2 min)  | Ouh, Yung-Taek (2 min) |
| 5-3. Prevalence and clinical characteristics of endometrial cancer by molecular classification in Korean patients                 | Han, Gwan Hee (3 min)  |
| Discussion (2 min)  | So, Kyung Ah (2 min)   |
| 5-4. Integrated genomic characterization of advanced endometrial cancer: KGOG consortium study                                    | Kim, Mi Kyung (3 min)  |
| Discussion (2 min)  | Jung, Dawn (2 min)     |

Coffee break (10 min)

7. Education session (Virtual) (40 min)

7-1. Androgen therapy Clinical Trial for Uterine Cancer

Katherine Kurnit (University of Chicago) (20 min)



7-2. Clinical Trial Suggestion for Gestational Trophoblastic Neoplasia
Neil S. Horowitz (Brigham & Women's Hospital/Dana Faber Cancer Institute) (20 min)



Distillation (1 min)

Kim, Se lk (1 min)

Perk, loops Youl (1 min)

8. Closing (1 min) Park, Jeong-Yeol (1 min)

# **Satellite Symposium I**

| Date  | 2022. 5. 14.                  |
|-------|-------------------------------|
| Time  | 12:30-13:20                   |
| Place | Room A                        |
| Chair | Kang, Soon-Beom/Kim, Jae-Weon |

## **Workshop Agenda**

1. Cutting-edge front-line maintenance therapy in BRCAm ovarian cancer — Shim, Seung-Hyuk (20 min) SOLO-1

2. The Era of precision medicine with Olaparib and bevacizumab as frontline maintenance in HRD+ ovarian cancer – PAOLA-1

Paik, E Sun (20 min)

3. Discussion (10 min)

## **Satellite Symposium II**

| Date  | 2022. 5. 14.                |
|-------|-----------------------------|
| Time  | 12:30-13:20                 |
| Place | Room B                      |
| Chair | Nam, Joo-Hyun/Kim, Dae Yeon |

## **Workshop Agenda**

- Molecular classification to unlock appropriate treatment option for endometrial cancer patients
   Hong, Jin Hwa (20 min)
- 2. The LEAP for advanced endometrial cancer: LEnvatinib And Pembrolizumab Ji, Young II (20 min)
- 3. Discussion (10 min)

## **Satellite Symposium III**

| Date  | 2022. 5. 14.               |
|-------|----------------------------|
| Time  | 12:30-13:20                |
| Place | Room C                     |
| Chair | Kim, Kyung Tae/Bae, Jaeman |

## **Workshop Agenda**

Preclinical evaluation of Niraparib – a novel PARP inhibitor for all platinum responders with ovarian cancer, regardless of biomarker status

Lee, Sanghoon (20 min)

2. Niraparib in frontline ovarian cancer with updated data

Choi, Min Chul (20 min)

3. Discussion (10 min)

#### Information +

#### | Meeting Venue |

BEXCO, Busan



#55 APEC-ro, Haeundae-gu, Busan (Postal Code 48060)

TEL. +82-51-740-7300 https://www.bexco.co.kr

#### | Accommodation |

#### **Centum Premier Hotel**

17, Centum 1-ro, Haeundae-gu, Busan, South Korea, 48060

TEL. +82+51-755-9000 premier\_rsvn@premierhotel.co.kr

Reservation deadline (Due date): April 29, 2022 (Fri) 17:00

| Room Type       | Weekday Rate(Krw) | Weekend Rate(Krw) | Number Of Rooms | Remark        |
|-----------------|-------------------|-------------------|-----------------|---------------|
| Single          | 70,000            | 80,000            |                 | 1 Single Bed  |
| Superior Double | 80,000            | 00 000            |                 | 1 Double Bed  |
| Superior Twin   |                   | 90,000            |                 | 2 Single Beds |
| Deluxe Double   | 90,000            | 100,000           |                 | 1 Double Bed  |
| Deluxe Twin     | 100,000           | 110,000           |                 | 2 Single Beds |
| Add Breakfast   | eakfast 13,200    |                   |                 | (pax)         |

Plus tax 10%

#### | Meeting Registration |

Registration Fee: 50,000 KRW (Until May 7, 20221)

Please register the way you w ant Online Registration **www.kgog.org** 

#### | Account Information |

Name of Bank : \* KB Kookmin Bank

Beneficiary Name: KGOG

Account Number: 445701-01-299238





#55 APEC-ro, Haeundae-gu, Busan



#### Subway

Busan Station(Line 1)  $\rightarrow$  Seomyeon Station(Line 2)  $\rightarrow$  Centum City(BEXCO) Station : Exit No.1 Fare : 1,400 KRW / Approx 45min

#### Subway Line





#### Bus

Express bus 1001

Busan Station → BEXCO Centum City Fare: 1,800 KRW / Approx 30min

City bus 40

Busan Station → BEXCO Centum City Fare: 1,200 KRW / Approx 40min



#### Taxi

Distance 13.93km / Approx 30 min Fare : 15,000 ~ 20,000 KRW

# KGOG 2022 Semi-Annual Meeting

Date: May 14 (Sat.), 2022
Venue: BEXCO, Busan